Skip to content
Bored Studies
RecruitingPhase 1

Phase 1 Study of C.001 in Retinal Degeneration

Cellio Therapeutics Inc · with California Institute for Regenerative Medicine (CIRM) · NCT07594236

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
15
US sites recruiting
1
Study start
April 7, 2026
Record last updated
August 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.

Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.

The primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.

Being studied: Injection

Conditions: Geographic Atrophy; Stargardt Disease; RPE-mediated Maculopathy; Age Related Macular Degeneration

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥18 years
  • Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease)
  • Visual acuity within protocol-defined limits
  • Stable ocular condition prior to enrollment
  • Medically suitable for ophthalmic surgery and anesthesia
  • Willingness to comply with study procedures and follow-up

Exclusion Criteria

  • Active or prior choroidal neovascularization (CNV)
  • Recent myocardial infarction or significant uncontrolled cardiovascular disease
  • Uncontrolled glaucoma
  • Significant ocular inflammatory disease
  • Recent intraocular surgery within protocol-defined timeframe
  • Active systemic infection
  • Poorly controlled diabetes (e.g., HbA1c >8.5%)
  • Participation in another investigational study within 3 months prior to screening

Recruiting US locations

  • Retina Vision Consultants

    Beverly Hills, CA 90210

    Site contact: Pradeep Prasad, MD · (310) 269-8565 · trials@celliotherapeutics.com

Study contacts (from the official record)

  • Clinical Trial Administrator · 999-999-9999 · trials@celliotherapeutics.com
All phase 1 studies in California →
Phase 1 Study of C.001 in Retinal Degeneration (NCT07594236) | Bored Studies